eli lilly clinical trials tirzepatide Breaking: New Retatrutide trial data just released. TRIUMPH-1 study results on the triple agonist. Lilly's trial on Retatrutide (triple agonist compound). 80 weeks. Phase 3 data. The results: At 12mg Lilly releases Zepbound® (tirzepatide) single-dose

What Is Retatrutide and Why Is It Different

For any injectable, microneedling and/or topical product: we advise that you conduct a patch test and wait in accordance with manufacturer advice (as per the product's packaging and/or enclosed literature) before proceeding to use it

GLP-1 agonists specifically bind to the GLP-1 receptor

Aggressive escalation that causes severe nausea often leads to poor adherence, missed injections, and worse outcomes than a slower, more tolerable approach

While clinicians and researchers use BMI as a population-level metric and as an individual screening tool to identify potential weight problems, many now advise that BMI alone is an incomplete measure of health

Cardiovascular Changes: High doses in certain individuals might slightly increase heart rate or blood pressure